1.1 	A bill for an act
1.2 	relating to public safety; clarifying the definition of hemp;amending Minnesota 
1.3 	Statutes 2020, sections 18K.02, subdivision 3; 152.02, subdivision 2.
1.4 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 	Section 1. Minnesota Statutes 2020, section 18K.02, subdivision 3, is amended to read:
1.6 		Subd. 3.Industrial hemp. "Industrial hemp" means the plant Cannabis sativa L. and 
1.7 	any part of the plant, whether growing or not, including the plant's seeds, and all the plant's 
1.8 	derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether 
1.9 	growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 
1.10 	percent on a dry weight basis. Industrial hemp is not marijuana as defined in section 152.01, 
1.11 	subdivision 9, or a tetrahydrocannabinol as described in section 152.02, subdivision 2, 
1.12 	paragraph (h), clause (2).

1.13 	EFFECTIVE DATE. This section is effective the day following final enactment.

1.14 	Sec. 2. Minnesota Statutes 2020, section 152.02, subdivision 2, is amended to read:
1.15 		Subd. 2.Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.16 	(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 
1.17 	following substances, including their analogs, isomers, esters, ethers, salts, and salts of 
1.18 	isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 
1.19 	and salts is possible:
1.20 	(1) acetylmethadol;
1.21 	(2) allylprodine;
2.1 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 
2.2 	acetate);
2.3 	(4) alphameprodine;
2.4 	(5) alphamethadol;
2.5 	(6) alpha-methylfentanyl benzethidine;
2.6 	(7) betacetylmethadol;
2.7 	(8) betameprodine;
2.8 	(9) betamethadol;
2.9 	(10) betaprodine;
2.10 	(11) clonitazene;
2.11 	(12) dextromoramide;
2.12 	(13) diampromide;
2.13 	(14) diethyliambutene;
2.14 	(15) difenoxin;
2.15 	(16) dimenoxadol;
2.16 	(17) dimepheptanol;
2.17 	(18) dimethyliambutene;
2.18 	(19) dioxaphetyl butyrate;
2.19 	(20) dipipanone;
2.20 	(21) ethylmethylthiambutene;
2.21 	(22) etonitazene;
2.22 	(23) etoxeridine;
2.23 	(24) furethidine;
2.24 	(25) hydroxypethidine;
2.25 	(26) ketobemidone;
2.26 	(27) levomoramide;
2.27 	(28) levophenacylmorphan;
3.1 	(29) 3-methylfentanyl;
3.2 	(30) acetyl-alpha-methylfentanyl;
3.3 	(31) alpha-methylthiofentanyl;
3.4 	(32) benzylfentanyl beta-hydroxyfentanyl;
3.5 	(33) beta-hydroxy-3-methylfentanyl;
3.6 	(34) 3-methylthiofentanyl;
3.7 	(35) thenylfentanyl;
3.8 	(36) thiofentanyl;
3.9 	(37) para-fluorofentanyl;
3.10 	(38) morpheridine;
3.11 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.12 	(40) noracymethadol;
3.13 	(41) norlevorphanol;
3.14 	(42) normethadone;
3.15 	(43) norpipanone;
3.16 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.17 	(45) phenadoxone;
3.18 	(46) phenampromide;
3.19 	(47) phenomorphan;
3.20 	(48) phenoperidine;
3.21 	(49) piritramide;
3.22 	(50) proheptazine;
3.23 	(51) properidine;
3.24 	(52) propiram;
3.25 	(53) racemoramide;
3.26 	(54) tilidine;
3.27 	(55) trimeperidine;
4.1 	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
4.2 	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
4.3 	methylbenzamide(U47700);
4.4 	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
4.5 	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
4.6 	(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropryl 
4.7 	fentanyl);
4.8 	(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
4.9 	(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
4.10 	(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl 
4.11 	fentanyl);
4.12 	(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
4.13 	(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
4.14 	(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide 
4.15 	(para-chloroisobutyryl fentanyl);
4.16 	(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl 
4.17 	fentanyl);
4.18 	(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide 
4.19 	(para-methoxybutyryl fentanyl);
4.20 	(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
4.21 	(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl 
4.22 	fentanyl or para-fluoroisobutyryl fentanyl);
4.23 	(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or 
4.24 	acryloylfentanyl);
4.25 	(72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl 
4.26 	fentanyl);
4.27 	(73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl 
4.28 	or 2-fluorofentanyl);
4.29 	(74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide 
4.30 	(tetrahydrofuranyl fentanyl); and
5.1 	(75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, 
5.2 	esters and ethers, meaning any substance not otherwise listed under another federal 
5.3 	Administration Controlled Substance Code Number or not otherwise listed in this section, 
5.4 	and for which no exemption or approval is in effect under section 505 of the Federal Food, 
5.5 	Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related 
5.6 	to fentanyl by one or more of the following modifications:
5.7 	(i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether 
5.8 	or not further substituted in or on the monocycle;
5.9 	(ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 
5.10 	haloalkyl, amino, or nitro groups;
5.11 	(iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, 
5.12 	hydroxyl, halo, haloalkyl, amino, or nitro groups;
5.13 	(iv) replacement of the aniline ring with any aromatic monocycle whether or not further 
5.14 	substituted in or on the aromatic monocycle; or
5.15 	(v) replacement of the N-propionyl group by another acyl group.
5.16 	(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, 
5.17 	and salts of isomers, unless specifically excepted or unless listed in another schedule, 
5.18 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
5.19 	(1) acetorphine;
5.20 	(2) acetyldihydrocodeine;
5.21 	(3) benzylmorphine;
5.22 	(4) codeine methylbromide;
5.23 	(5) codeine-n-oxide;
5.24 	(6) cyprenorphine;
5.25 	(7) desomorphine;
5.26 	(8) dihydromorphine;
5.27 	(9) drotebanol;
5.28 	(10) etorphine;
5.29 	(11) heroin;
5.30 	(12) hydromorphinol;
6.1 	(13) methyldesorphine;
6.2 	(14) methyldihydromorphine;
6.3 	(15) morphine methylbromide;
6.4 	(16) morphine methylsulfonate;
6.5 	(17) morphine-n-oxide;
6.6 	(18) myrophine;
6.7 	(19) nicocodeine;
6.8 	(20) nicomorphine;
6.9 	(21) normorphine;
6.10 	(22) pholcodine; and
6.11 	(23) thebacon.
6.12 	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any 
6.13 	quantity of the following substances, their analogs, salts, isomers (whether optical, positional, 
6.14 	or geometric), and salts of isomers, unless specifically excepted or unless listed in another 
6.15 	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is 
6.16 	possible:
6.17 	(1) methylenedioxy amphetamine;
6.18 	(2) methylenedioxymethamphetamine;
6.19 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
6.20 	(4) n-hydroxy-methylenedioxyamphetamine;
6.21 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
6.22 	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
6.23 	(7) 4-methoxyamphetamine;
6.24 	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
6.25 	(9) alpha-ethyltryptamine;
6.26 	(10) bufotenine;
6.27 	(11) diethyltryptamine;
6.28 	(12) dimethyltryptamine;
7.1 	(13) 3,4,5-trimethoxyamphetamine;
7.2 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
7.3 	(15) ibogaine;
7.4 	(16) lysergic acid diethylamide (LSD);
7.5 	(17) mescaline;
7.6 	(18) parahexyl;
7.7 	(19) N-ethyl-3-piperidyl benzilate;
7.8 	(20) N-methyl-3-piperidyl benzilate;
7.9 	(21) psilocybin;
7.10 	(22) psilocyn;
7.11 	(23) tenocyclidine (TPCP or TCP);
7.12 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
7.13 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
7.14 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
7.15 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
7.16 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
7.17 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
7.18 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
7.19 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
7.20 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
7.21 	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
7.22 	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
7.23 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
7.24 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
7.25 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
7.26 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
7.27 	(2-CB-FLY);
8.1 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
8.2 	(40) alpha-methyltryptamine (AMT);
8.3 	(41) N,N-diisopropyltryptamine (DiPT);
8.4 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
8.5 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
8.6 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
8.7 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
8.8 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
8.9 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
8.10 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
8.11 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
8.12 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
8.13 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
8.14 	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
8.15 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
8.16 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
8.17 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
8.18 	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
8.19 	(57) methoxetamine (MXE);
8.20 	(58) 5-iodo-2-aminoindane (5-IAI);
8.21 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
8.22 	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
8.23 	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
8.24 	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
8.25 	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
8.26 	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
8.27 	(65) N,N-Dipropyltryptamine (DPT);
9.1 	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
9.2 	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
9.3 	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
9.4 	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
9.5 	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, 
9.6 	ethketamine, NENK);
9.7 	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
9.8 	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
9.9 	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
9.10 	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii 
9.11 	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, 
9.12 	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, 
9.13 	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not 
9.14 	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian 
9.15 	Church, and members of the American Indian Church are exempt from registration. Any 
9.16 	person who manufactures peyote for or distributes peyote to the American Indian Church, 
9.17 	however, is required to obtain federal registration annually and to comply with all other 
9.18 	requirements of law.
9.19 	(f) Central nervous system depressants. Unless specifically excepted or unless listed in 
9.20 	another schedule, any material compound, mixture, or preparation which contains any 
9.21 	quantity of the following substances, their analogs, salts, isomers, and salts of isomers 
9.22 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
9.23 	(1) mecloqualone;
9.24 	(2) methaqualone;
9.25 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
9.26 	(4) flunitrazepam;
9.27 	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, 
9.28 	methoxyketamine);
9.29 	(6) tianeptine;
9.30 	(7) clonazolam;
10.1 	(8) etizolam;
10.2 	(9) flubromazolam; and
10.3 	(10) flubromazepam.
10.4 	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
10.5 	material compound, mixture, or preparation which contains any quantity of the following 
10.6 	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the 
10.7 	analogs, salts, isomers, and salts of isomers is possible:
10.8 	(1) aminorex;
10.9 	(2) cathinone;
10.10 	(3) fenethylline;
10.11 	(4) methcathinone;
10.12 	(5) methylaminorex;
10.13 	(6) N,N-dimethylamphetamine;
10.14 	(7) N-benzylpiperazine (BZP);
10.15 	(8) methylmethcathinone (mephedrone);
10.16 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
10.17 	(10) methoxymethcathinone (methedrone);
10.18 	(11) methylenedioxypyrovalerone (MDPV);
10.19 	(12) 3-fluoro-N-methylcathinone (3-FMC);
10.20 	(13) methylethcathinone (MEC);
10.21 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
10.22 	(15) dimethylmethcathinone (DMMC);
10.23 	(16) fluoroamphetamine;
10.24 	(17) fluoromethamphetamine;
10.25 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
10.26 	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
10.27 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
11.1 	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or 
11.2 	naphyrone);
11.3 	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
11.4 	(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
11.5 	(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
11.6 	(25) 4-methyl-N-ethylcathinone (4-MEC);
11.7 	(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
11.8 	(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
11.9 	(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
11.10 	(29) 4-fluoro-N-methylcathinone (4-FMC);
11.11 	(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
11.12 	(31) alpha-pyrrolidinobutiophenone (α-PBP);
11.13 	(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
11.14 	(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
11.15 	(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
11.16 	(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
11.17 	(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
11.18 	(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
11.19 	(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
11.20 	(39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone); 
11.21 	and
11.22 	(40) any other substance, except bupropion or compounds listed under a different 
11.23 	schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 
11.24 	1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the 
11.25 	compound is further modified in any of the following ways:
11.26 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
11.27 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
11.28 	system by one or more other univalent substituents;
11.29 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
12.1 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
12.2 	methoxybenzyl groups; or
12.3 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
12.4 	(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
12.5 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
12.6 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
12.7 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
12.8 	of the isomers, esters, ethers, or salts is possible:
12.9 	(1) marijuana;
12.10 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic 
12.11 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
12.12 	of the plant, or synthetic substances with similar chemical structure and pharmacological 
12.13 	activity to those substances contained in the plant or resinous extract, including, but not 
12.14 	limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
12.15 	cis or trans tetrahydrocannabinol; but not including tetrahydrocannabinols contained in 
12.16 	hemp as defined in section 152.22, subdivision 5a;
12.17 	(3) synthetic cannabinoids, including the following substances:
12.18 	(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
12.19 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
12.20 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
12.21 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
12.22 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
12.23 	naphthoylindoles include, but are not limited to:
12.24 	(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
12.25 	(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
12.26 	(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
12.27 	(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
12.28 	(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
12.29 	(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
12.30 	(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
12.31 	(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
13.1 	(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
13.2 	(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
13.3 	(ii) Napthylmethylindoles, which are any compounds containing a 
13.4 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 
13.5 	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
13.6 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
13.7 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
13.8 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
13.9 	(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
13.10 	(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
13.11 	(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole 
13.12 	structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
13.13 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.14 	2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 
13.15 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
13.16 	naphthoylpyrroles include, but are not limited to, 
13.17 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
13.18 	(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene 
13.19 	structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, 
13.20 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.21 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any 
13.22 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
13.23 	naphthylemethylindenes include, but are not limited to, 
13.24 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
13.25 	(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
13.26 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
13.27 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.28 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
13.29 	extent, whether or not substituted in the phenyl ring to any extent. Examples of 
13.30 	phenylacetylindoles include, but are not limited to:
13.31 	(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
13.32 	(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
13.33 	(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
14.1 	(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
14.2 	(vi) Cyclohexylphenols, which are compounds containing a 
14.3 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic 
14.4 	ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
14.5 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted 
14.6 	in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not 
14.7 	limited to:
14.8 	(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
14.9 	(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
14.10 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
14.11 	(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
14.12 	-phenol (CP 55,940).
14.13 	(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure 
14.14 	with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 
14.15 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
14.16 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
14.17 	extent and whether or not substituted in the phenyl ring to any extent. Examples of 
14.18 	benzoylindoles include, but are not limited to:
14.19 	(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
14.20 	(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
14.21 	(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 
14.22 	48,098 or Pravadoline).
14.23 	(viii) Others specifically named:
14.24 	(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
14.25 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
14.26 	(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
14.27 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
14.28 	(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
14.29 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
14.30 	(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
15.1 	(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
15.2 	(XLR-11);
15.3 	(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
15.4 	(AKB-48(APINACA));
15.5 	(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
15.6 	(5-Fluoro-AKB-48);
15.7 	(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
15.8 	(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
15.9 	(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide 
15.10 	(AB-PINACA);
15.11 	(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 
15.12 	1H-indazole-3-carboxamide (AB-FUBINACA);
15.13 	(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- 
15.14 	indazole-3-carboxamide(AB-CHMINACA);
15.15 	(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate 
15.16 	(5-fluoro-AMB);
15.17 	(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
15.18 	(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) 
15.19 	(FUBIMINA);
15.20 	(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo 
15.21 	[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
15.22 	(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) 
15.23 	-1H-indole-3-carboxamide (5-fluoro-ABICA);
15.24 	(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
15.25 	-1H-indole-3-carboxamide;
15.26 	(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
15.27 	-1H-indazole-3-carboxamide;
15.28 	(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
15.29 	(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1 
15.30 	H-indazole-3-carboxamide (MAB-CHMINACA);
16.1 	(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide 
16.2 	(ADB-PINACA);
16.3 	(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
16.4 	(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
16.5 	3-carboxamide. (APP-CHMINACA);
16.6 	(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
16.7 	(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
16.8 	(ix) Additional substances specifically named:
16.9 	(A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 
16.10 	H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);
16.11 	(B) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide 
16.12 	(4-CN-Cumyl-Butinaca);
16.13 	(C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);
16.14 	(D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 
16.15 	H-indazole-3-carboxamide (5F-ABPINACA);
16.16 	(E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate 
16.17 	(MDMB CHMICA);
16.18 	(F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 
16.19 	(5F-ADB; 5F-MDMB-PINACA); and
16.20 	(G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl) 
16.21 	1H-indazole-3-carboxamide (ADB-FUBINACA).
16.22 	(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended 
16.23 	for human consumption.

16.24 	EFFECTIVE DATE. This section is effective the day following final enactment.